The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Peptide And Oligonucleotide CDMO Market Projected To Become By 2030 Based On Its 2026 Valuation?
The market for peptide and oligonucleotide CDMO services has expanded considerably over recent years. This market is projected to expand from $2.42 billion in 2025 to $2.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. Historically, this expansion has been driven by several factors, including the rise in peptide-based therapeutics, the growing intricacy of synthetic oligonucleotides, drug developers’ constrained in-house manufacturing capacities, increasingly stringent regulatory compliance demands, and the initial uptake of antisense and peptide drugs.
The peptide and oligonucleotide cdmo market size is anticipated to undergo significant expansion over the next few years, with projections indicating it will reach $4.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. This growth throughout the forecast period is propelled by factors such as the expanding pipelines of oligonucleotide therapeutics, increased investment in drugs for rare diseases and oncology, a heightened demand for rapid production of clinical trial materials, a growing preference for specialized CDMO partnerships, and continuous advancements in solid-phase synthesis technologies. Furthermore, notable trends expected in this period include an increase in the outsourcing of peptide and oligonucleotide manufacturing, a rising need for CGMP-compliant production of complex molecules, the expansion of comprehensive end-to-end development and manufacturing services, a sharpened focus on high-potency and high-purity therapeutics, and a wider adoption of scalable and flexible manufacturing platforms.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Peptide And Oligonucleotide CDMO Market?
The increasing integration of personalized medicine is projected to fuel expansion within the peptide and oligonucleotide CDMO markets in the future. This healthcare approach involves customizing medical decisions and therapies based on distinct individual traits like genetics, environment, and lifestyle. Its rising popularity stems from various elements, including breakthroughs in genomic technologies, an enhanced comprehension of disease mechanisms at a molecular scale, and a need for more potent and specific treatment pathways designed for individual patients’ genetic makeup and medical backgrounds. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, creating bespoke therapeutic peptides and oligonucleotides to meet specific patient requirements. An example of this trend is evident in February 2024, as the Personalized Medicine Coalition, a UK-based organization promoting personalized medicine adoption, noted that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the expanding embrace of personalized medicine is stimulating market expansion for peptide and oligonucleotide CDMOs.
What Segment Groups Are Identified Within The Peptide And Oligonucleotide CDMO Market?
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
What Trends Are Advancing Progress In The Peptide And Oligonucleotide CDMO Market?
Leading companies within the peptide and oligonucleotide CDMO market are concentrating on establishing strategic collaborations to improve their service portfolios, expand their technological proficiency, and extend their market influence. Partnerships for peptide development and production denote cooperative agreements between two entities dedicated to the advancement and manufacturing of peptide-based therapeutic products. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), entered into a partnership with Numaferm GmbH, a Germany-based biotechnology company, for the development and production of peptides. This alliance seeks to utilize PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s specialized knowledge in sustainable peptide manufacturing and biochemical production platforms. The collaboration is centered on jointly exploring the creation of appropriate peptide candidates with the objective of achieving more sustainable production of peptide-based APIs.
Which Companies Hold Significant Positions In The Peptide And Oligonucleotide CDMO Market?
Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
Read the full peptide and oligonucleotide cdmo market report here:
Which Regions Are Projected To Dominate The Peptide And Oligonucleotide CDMO Market In The Coming Years?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Peptide And Oligonucleotide CDMO Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp
Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company
Peptide And Oligonucleotide Cdmo Market Report 2026
Oligonucleotides Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model